Showing 5261-5270 of 21466 results for "".
- Blood X Chromosome Loss Linked to Lower Natural Conception Oddshttps://reachmd.com/news/blood-x-chromosome-loss-linked-to-lower-natural-conception-odds/2487133/Key Takeaways Higher hematopoietic LOX in peripheral blood was associated with a lower likelihood of natural conception in this case-control cohort. Peripheral-blood %LOX increased with age and did not track with AMH or FSH levels. No clear as
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://reachmd.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- CMSC and NeurologyLive Name 2026 Giants of Multiple Sclerosishttps://reachmd.com/news/cmsc-and-neurologylive-name-2026-giants-of-multiple-sclerosis/2487138/Key Takeaways Seven honorees were named across seven disciplines in the 2026 class. Finalists were determined by an advisory board, and category inductees were chosen by a selection committee of more than 30 MS professionals. Patricia K. Coyle
- Low-Dose Naltrexone in Major Depressive Disorder: Trial Findingshttps://reachmd.com/news/low-dose-naltrexone-mdd/2487123/Key Takeaways In patients with moderate major depressive disorder, adjunctive low-dose naltrexone was not associated with greater improvement than placebo. No effect was seen on hsCRP or on BDI-II, BADS, SF-36, POMS, and SicknessQ measures, and baselin
- Study: Hair Care Regimen May Enhance Minoxidil Response in Women With Hair Losshttps://reachmd.com/news/seen-study-suggests-hair-care-regimen-may-enhance-minoxidil-response-in-women-with-hair-loss/2487130/SEEN Hair Care presented new clinical findings at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE), suggesting that a non-comedogenic, non-irritating hair care regimen may improve outcomes with topical minoxidil 5% foam in women with
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://reachmd.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- Global Burden Of Nontraumatic Subarachnoid Hemorrhagehttps://reachmd.com/news/global-burden-of-nontraumatic-subarachnoid-hemorrhage/2487179/Key Takeaways Nontraumatic subarachnoid hemorrhage carried a large global burden in 2021, with lower age-standardized incidence, prevalence, mortality, and disability-adjusted life-year rates than in 1990 even as absolute incident and prevalent case counts rose
- Aesthetic Meet 2026: The Aesthetic Society Names Dr. Jamil Ahmad Presidenthttps://reachmd.com/news/aesthetic-meet-2026-the-aesthetic-society-names-dr-jamil-ahmad-president/2487120/The Aesthetic Society has named Jamil Ahmad, MD, as its President, and The Aesthetic Foundation has named David A. Sieber, MD, as President, during The Aesthetic MEET 2026 in Boston. Dr. Ahmad assumes leadership as The Society reports membership growth of more than 30%, with new members fr
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://reachmd.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- Subcutaneous Guselkumab Meets Week 12 Endpoint In Ulcerative Colitishttps://reachmd.com/news/subcutaneous-guselkumab-meets-week-12-endpoint-in-ulcerative-colitis/2487100/Key Takeaways Subcutaneous guselkumab induction was associated with higher week 12 clinical remission than placebo. Week 24 clinical remission remained higher in both guselkumab groups than in the placebo group. Adverse events were reported at